PURPOSE: Factors affecting the adoption of non-curative initial management (NCIM) in the United States for low-risk prostate cancer (PCa) on a population-based level are unknown. Our objectives were to measure temporal trends in the proportion of low- and intermediate-risk PCa patients electing NCIM in the US and analyze the association of factors affecting management choice.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIALS AND METHODS: We identified 465,591 and 237,257 men diagnosed with low- or intermediate-risk PCa using the National Cancer Database (NCDB) and Surveillance, Epidemiology, and End Results (SEER) (2004-2010), respectively. We measured the proportion of men electing NCIM and used multivariate logistic regression analyses to evaluate factors affecting management choice.
RESULTS: Over the study period, among low-risk patients, NCIM increased in SEER from 21% to 32% and in the NCDB from 13% to 20% (both p< 0.001). This increase was not reflected in our overall study population (SEER: 20% to 22% NCDB: 11% to 13%) as the proportion of patients with Gleason ≤ 6 decreased over time (SEER: 61% to 49% NCDB: 61% to 45%). From 2004 to 2010, older age, lower PSA, earlier clinical stage, increased comorbidity index, and not being married were associated with a higher likelihood of NCIM (all p< 0.05).
CONCLUSIONS: Two, independently-managed population-based datasets confirm a temporal increase in NCIM among low-risk patients that did not translate into greater use overall among low- and intermediate-risk patients combined. These contrasting results are likely due to grade migration resulting in fewer men being classified as low-risk based on Gleason score.
Weiner AB, Patel SG, Etzioni R, Eggener SE. Are you the author?
Pritzker School of Medicine Fellow, The University of Chicago Medical Center, Chicago, Illinois; Urologic Oncology Fellow, The University of Chicago Medical Center, Chicago, Illinois; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; Associate Professor of Surgery Urologic Oncology Fellow, The University of Chicago Medical Center, Chicago, Illinois.
Reference: J Urol. 2014 Aug 5. pii: S0022-5347(14)04151-2.